The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
R | Respiratory system | |
2
|
R03 | Drugs for obstructive airway diseases | |
3
|
R03D | Other systemic drugs for obstructive airway diseases | |
4
|
R03DX | Other systemic drugs for obstructive airway diseases | |
5
|
R03DX11 |
| Active Ingredient |
|---|
|
Tezepelumab is a monoclonal antibody (IgG2λ) directed against thymic stromal lymphopoietin (TSLP), preventing its interaction with the heterodimeric TSLP receptor. In asthma, both allergic and non-allergic triggers induce TSLP production. Blocking TSLP with tezepelumab reduces a broad spectrum of biomarkers and cytokines associated with airway inflammation; however, the mechanism of action of tezepelumab in asthma has not been definitively established. |
| Document | Type | Information Source | |
|---|---|---|---|
| TEZSPIRE Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.